Transfusion Journal/ transfusion.org
Aug 28, 2025, 18:54
Albert Farrugia: When Will FV Deficiency Get the Attention It Deserves?
Albert Farrugia, Clinical professor at The University of Western Australia, shared an insightful post on LinkedIn:
“The largest series, as far as I’m aware, on the use of FX concentrate in this extremely rare deficiency.
When are we going to see some effort for FV deficiency. I anticipate efficacy with many of the bypassing agents.
It’s disappointing not to see FV deficient patients included in the trials.
Read the full article:”
Article: Characterization and management of patients with hereditary factor X deficiency: A case series
Authors: Meera Chitlur, Lauren E. Amos, Mark T. Reding, Cynthia Sabo, Suchitra S. Acharya
Stay updated with Haemostasis Today.
-
Jan 11, 2026, 06:18Filippo Cademartiri on Why Vascular Health Is Cognitive Health
-
Jan 11, 2026, 06:01Maira Dastgir N on Cannabis-Induced Ischemic Stroke
-
Jan 11, 2026, 05:51Nishant K Mishra on Preventing Post-Stroke Seizures
-
Jan 11, 2026, 05:41Indunil Karunarathna on CSF Xanthochromia in SAH
-
Jan 11, 2026, 05:22Mitchell Elkind on The New York Times Brain Health Challenge: Food Is Brain Medicine!
-
Jan 11, 2026, 03:55Building Better Care for Bleeding Disorders in Zambia․ Chatowa’s Journey
-
Jan 11, 2026, 03:54Unsupervised Machine Learning for Patient Stratification in Cardiovascular Disease
-
Jan 11, 2026, 03:54DAPT De-escalation After PCI․ Where Do We Stand Today?
-
Jan 11, 2026, 03:53Mostafa Faisal Mohammed: Avatrombopag in Aplastic Anemia